Study of NMS-1286937 in Adult Patients With Advanced/Metastatic Solid Tumors

Inclusion Criteria: * Advanced/metastatic solid tumors, for which no effective standard therapy exist * Adult patients (age \>/= 18) * ECOG performance status (PS) 0 or 1 * Life expectancy of at least 3 months * Adequate renal, liver function and bone marrow reserve * Prior cancer therapy allowed, with max 4 regimens of chemotherapy. Washout: at least 4 wks (6 wks for nitrosoureas, mitomycin C and liposomal doxorubicin) and all toxicities recovered to CTC Grade \</=1 * Prior radiotherapy allowed if no more than 25% of BM reserve irradiated * Women and men of child producing potential should agree to use effective contraception * Capability to swallow capsules intact Exclusion Criteria: * Known uncontrolled/symptomatic brain metastases * Currently active second malignancy * Major surgery in the last 4 wks * Any of the following in the past 6 months: myocardial infarction, unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis * Pregnancy or breast-feeding women * Known active infections * History of drug allergic reactions * Gastrointestinal disease or other malabsorption syndromes that would impact on drug absorption. * Documented gastrointestinal ulcer * Other severe concurrent acute or chronic medical or psychiatric condition that could compromise protocol objectives